Update of the calcium-sensing receptor and calcimimetics

Current Opinion in Endocrinology and Diabetes

Volumn 8, Issue 1, 2001, Pages 29-33

  Rose, B ^a   Shoback, D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (3 METHOXYPHENYL) N (3 PHENYLPROPYL)ETHYLAMINE; CALCIUM; CALCIUM CHANNEL STIMULATING AGENT; CALCIUM SENSING RECEPTOR; CINACALCET; G PROTEIN COUPLED RECEPTOR; N [3 (2 CHLOROPHENYL)PROPYL] 1 (3 METHOXYPHENYL)ETHYLAMINE; PARATHYROID HORMONE; UNCLASSIFIED DRUG;

CALCIUM HOMEOSTASIS; CALCIUM METABOLISM; DRUG EFFECT; DRUG MECHANISM; GENE MUTATION; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; HYPOCALCEMIA; NONHUMAN; PARATHYROID HYPERPLASIA; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; RECEPTOR INTRINSIC ACTIVITY; RENAL OSTEODYSTROPHY; REVIEW; SIGNAL TRANSDUCTION;

EID: 0035141968     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/00060793-200102000-00006     Document Type: Review

References (36)

1. 2+-sensing receptor from bovine parathyroid
2. 2+)-sensing receptor (CAR): Roles in cell signaling and control of diverse cellular functions
3. Calcium-sensing receptor and calcimimetic agents
4. 2+ receptor in rats
5. 2+ sensing receptor in rat intestine
6. Immunocytochemical localization of the extracellular calcium-sensing receptor in normal and malignant human large intestinal mucosa
7. Expression of calcium-sensing receptor and characterization of intracellular signaling in human pituitary adenomas
8. Changes in calcium responsiveness and handling during keratinocyte differentiation. Potential role of the calcium receptor
9. Effects of a calcium receptor activator on the cellular response to calcium in human keratinocytes
10. Failure to detect the extracellular calciumsensing receptor (CasR) in human osteoblast cell lines
11. Expression and signal transduction of calcium-sensing receptors in cartilage and bone
12. High extracellular calcium inhibits osteoclast-like cell formation by directly acting on the calciumsensing receptor existing in osteoclast precursor cells
13. A familial syndrome of hypocalcemia with hypercalciuria due to mutations in the calcium-sensing receptor
14. 2+-sensing receptor
15. 2+-sensing receptor gene cause autosomal dominant and sporadic hypoparathyroidism
16. 2+-sensing receptor gene mutation
17. Familial hypoparathyroidism: Identification of a novel gain of function mutation in transmembrane domain 5 of the calcium-sensing receptor
18. A novel activating mutation in the calcium-sensing receptor gene associated with a family of autosomal dominant hypocalcemia
19. Autosomal dominant hypoparathyroidism associated with short stature and premature osteoarthritis
20. 2+ receptor
21. Familial hypercalcemia and hypercalciuria caused by a novel mutation in the cytoplasmic tail of the calcium receptor
22. Casting new light on the clinical spectrum of neonatal severe hyperparathyroidism
23. An adult patient with severe hypercalcemia and hypocalciuria due to a novel homozygous inactivating mutation of calcium-sensing receptor
24. Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism
25. Calcium-sensing receptor expression and signaling in human parathyroid adenomas and primary hyperplasia
26. Cloning and characterization of two promoters for the human calcium-sensing receptor (CaSR) and changes of CaSR expression in parathyroid adenomas
27. The calcium receptor and calcimimetics
28. Calcimimetics with potent and selective activity on the parathyroid calcium receptor
29. Calcimimetic NPS R-568 prevents parathyroid hyperplasia in rats with severe secondary hyperparathyroidism
30. Activation of the calcium receptor by a calcimimetic compound halts the progression of secondary hyperparathyroidism in uremic rats
31. The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency: Control of parathyroid ceil growth via a calcium receptor
32. NPS R-568: A type II calcimimetic compound that acts on parathyroid cell calcium receptor of rats to reduce plasma levels of parathyroid hormone and calcium
33. Daily intermittent decreases in serum levels of parathyroid hormone have an anabolic-like action on the bones of uremic rats with low-turnover bone and osteomaiacia
34. Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism
35. Calcimimetic AMG 073 normalizes total serum calcium in patients with primary hyperparathyroidism
36. The calcimimetic, R-568, lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism